Jun Lu

Prof. Dr. Jun Lu

Hepatology and Cancer Biotherapy Ward, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, P.R.China
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2016 in Inflammation
Verified
Journal Article
Closed access
PDF file
FYFan Yang
Fan Yang
CFChang Feng
Chang Feng
XZXiaodong Zhang
Xiaodong Zhang
JLJun Lu
Jun Lu
Yong ZhaoYong Zhao
Yong Zhao

11 June 2014 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
YXYun Xie
Yun Xie
QYQinwei Yao
Qinwei Yao
ABAzeem Mehmood Butt
Azeem Mehmood Butt
JGJia Guo
Jia Guo
ZTZhou Tian
Zhou Tian
JLJun Lu
Jun Lu
MicroRNAs (miRNAs) represent a class of evolutionarily conserved, non-coding small RNAs (18–25 nt) that have emerged as master regulators of several biological processes. Recently, circulating miRNAs have also been reported to be promising biomarkers for various pathological conditions. In the present study, we report the comparative expression profiling of microRNA-101 (miR-101) in serum and tissue samples from chronic hepatitis B (CHB), HBV-associated liver cirrhosis (HBV-LC), and HBV-associated hepatocellular carcinoma (HBV-HCC) patients and healthy controls. The serum miR-101 levels were found to be significantly downregulated in the HBV-HCC patients compared with the HBV-LC patients (P < 0.001), CHB patients (P < 0.001) and healthy controls but were upregulated in the HBV-LC patients compared with the CHB patients (P < 0.001) and healthy controls (P < 0.001). Consistent with the serum data, the expression of miR-101 was also upregulated and downregulated in the HBV-LC and HBV-HCC tissue samples, resp...

2 March 2016 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
FYFan Yang
Fan Yang
YLYang Li
Yang Li
TWTingting Wu
Tingting Wu
NNNing Na
Ning Na
YZYang Zhao
Yang Zhao
Yong ZhaoYong Zhao
Yong Zhao

13 July 2021 in The Oncologist
Verified
Journal Article
Open access
PDF file
YGYao Gao
Yao Gao
JGJia Guo
Jia Guo
XBXuli Bao
Xuli Bao
FXFang Xiong
Fang Xiong
YMYanpin Ma
Yanpin Ma
JLJun Lu
Jun Lu
Lessons Learned Administration of autologous invariant natural killer T (iNKT) cells was safe and well-tolerated in patients with hepatocellular carcinoma (Barcelona Clinic Liver Cancer stage B/C). Expanded iNKT cells produced T-helper 1–like responses with possible antitumor activity. No severe adverse events were observed in any of the enrolled patients, including one patient who received 1010 in vitro–expanded autologous iNKT cells as a single infusion. Background Invariant natural killer T cells co-express T-cell antigen receptor and natural killer (NK) cell receptors. Invariant natural killer T (iNKT) cells exhibit antitumor activity, but their numbers and functions are impaired in patients with hepatocellular carcinoma (HCC). The adoptive transfer of iNKT cells might treat advanced HCC. Methods This phase I study (NCT03175679) enrolled 10 patients with HCC (Barcelona Clinic Liver Cancer [BCLC] stage B/C) at Beijing YouAn Hospital (April 2017 to May 2018). iNKT cells isolated from peripheral blood mononuclear cells (PBMCs) were expanded and alpha-galactosylceramide (α-GalCer)–pulsed. Dosage escalated from 3 × 107 to 6 × 107 to 9 × 107 cells/m2 (3+3 design). An exploratory dose trial (1 × 1010 cells/m2) was conducted in one patient. Results Expanded iNKT cells produced greater quantities of T-helper 1 (Th1) cytokines (e.g., interferon-gamma, perforin, and granzyme B) but less interleukin-4 than nonexpanded iNKT cells. Circulating numbers of iNKT cells and activated NK cells were increased after iNKT cell infusion. Most treatment-related adverse events were grade 1–2, and three grade 3 adverse events were reported; all resolved without treatment. Four patients were progression-free at 5.5, 6, 7, and 11 months after therapy, and one patient was alive and without tumor recurrence at the last follow-up. Five patients died at 1.5 to 11 months after treatment. Conclusion Autologous iNKT cell treatment is safe and well-tolerated. Expanded iNKT cells produce Th1-like responses with possible antitumor activity. The antitumor effects of iNKT cell infusion in patients with advanced HCC merit further investigation.


7 June 2024 in Chinese Medical Journal
Verified
Journal Article
Open access
XWXiaoxia Wang
Xiaoxia Wang
JLJun Lu
Jun Lu
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Its high recurrence rate and lack of effective control drugs result in a 5-year survival rate of only about 10%. HCC is a tumor regulated by the immune system. Significant breakthroughs have occurred in treating solid tumors with immunotherapy in recent years. Various immunotherapies, such as immune checkpoint inhibitors (ICIs), including combination therapies, have demonstrated promising therapeutic effects in both clinical applications and research. Other immunotherapies, such as adoptive cell therapies and oncolytic viruses, are also emerging, offering hope for addressing long-term survival issues in HCC. This article reviews current commonly used immunotherapy strategies and the latest research findings for reference.